Consumer medicine information

APO-Dorzolamide/Timolol 20/5 Eye Drops

Dorzolamide; Timolol

BRAND INFORMATION

Brand name

APO-Dorzolamide/Timolol 20/5 Eye Drops

Active ingredient

Dorzolamide; Timolol

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using APO-Dorzolamide/Timolol 20/5 Eye Drops.

What is in this leaflet

Read this leaflet carefully before taking your medicine.

This leaflet answers some common questions about dorzolamide/timolol. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

The information in this leaflet was last updated on the date listed on the last page. More recent information on this medicine may be available.

Ask your doctor or pharmacist:

  • if there is anything you do not understand in this leaflet,
  • if you are worried about taking your medicine, or
  • to obtain the most up-to-date information.

You can also download the most up to date leaflet from www.apotex.com.au.

All medicines have risks and benefits. Your doctor has weighed the risks of you using this medicine against the benefits they expect it will have for you.

Pharmaceutical companies cannot give you medical advice or an individual diagnosis.

Keep this leaflet with your medicine. You may want to read it again.

What this medicine is used for

The name of your medicine is APO-Dorzolamide/Timolol eye drops. It contains the active ingredients dorzolamide (22.3 mg of dorzolamide hydrochloride) and timolol (6.8 mg of timolol maleate).

It is used to treat lower raised pressure in the eye and to treat glaucoma. Glaucoma is a condition in which the pressure of fluid in the eye may be high. However, some people with glaucoma may have normal eye pressure. Also, some people with raised eye pressure may not have glaucoma.

Glaucoma is usually caused by a build-up of the fluid which flows through the eye. This build up occurs because the fluid drains out of your eye more slowly than it is being pumped in. Since new fluid continues to enter the eye, joining the fluid already there, the pressure continues to rise. This raised pressure may damage the back of the eye resulting in gradual loss of sight. Damage can progress so slowly that the person is not aware of this gradual loss of sight.

Sometimes even normal eye pressure is associated with damage to the back of the eye.

There are usually no symptoms of glaucoma. The only way of knowing that you have glaucoma is to have your eye pressure, optic nerve and visual field checked by an eye specialist or optometrist. If glaucoma is not treated it can lead to serious problems. You may have no symptoms but eventually glaucoma can lead to total blindness. In fact, untreated glaucoma is one of the most common causes of blindness.

Although dorzolamide/timolol helps control your glaucoma it does not cure it.

For more information about glaucoma, contact Glaucoma Australia Inc., PO Box 420, Crows Nest 1585, telephone 02 9906 6640.

Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed this medicine for another reason.

This medicine is available only with a doctor's prescription.

How it works

Dorzolamide/timolol contains two active ingredients, dorzolamide (as hydrochloride) and timolol (as maleate). Both of these active ingredients lower pressure in the eye by reducing the production of fluid, but they do this in different ways.

Dorzolamide (as hydrochloride) belongs to a family of medicines called carbonic anhydrase inhibitors.

Timolol (as maleate) belongs to a family of medicines called beta-blockers.

There is no evidence that this medicine is addictive.

Use in children

This medicine should not be used in children.

The safety and effectiveness of dorzolamide in children have not been established.

Before you take this medicine

When you must not take it

Do not take this medicine if:

  • You have or have had any of the following:
    - serious breathing problem such as asthma, chronic obstructive lung disease (emphysema), or other breathing problems.
    - heart conditions, such as slow heart rate, an irregular heartbeat, or heart failure.
  • You are breastfeeding or intend to breastfeed.
    Your baby may absorb this medicine from breast milk and therefore is a possibility of harm to the baby.
  • You are hypersensitive to, or have had an allergic reaction to, dorzolamide/timolol or any of the ingredients listed at the end of this leaflet.
    Symptoms of an allergic reaction may include: shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue, throat or other parts of the body; rash, itching or hives on the skin; fainting; or hay fever-like symptoms.
    If you think you are having an allergic reaction, do not take any more of the medicine and contact your doctor immediately or go to the Accident and Emergency department at the nearest hospital.
  • The expiry date (EXP) printed on the pack has passed.
  • The packaging is torn, shows signs of tampering or it does not look quite right.
  • Do not put the eye drops into your eye(s) while you are wearing soft contact lenses.
    The preservative in dorzolamide/timolol (benzalkonium chloride) may be deposited in soft contact lenses. You can put soft contact lenses back into your eyes at least 15 minutes after you have used dorzolamide/timolol.

Before you start to take it

Before you start taking this medicine, tell your doctor if:

  1. You have allergies to:
  • any other medicines
  • any other substances, such as foods, preservatives or dyes.
  1. You have or have had any medical conditions, especially the following:
  • heart problems (such as coronary heart disease, heart failure or low blood pressure)
  • heart rate disturbances (such as slow or irregular heartbeats)
  • poor blood circulation problems (such as Raynaud's syndrome)
  • lung or breathing problems (such as asthma or chronic obstructive lung disease)
  • diabetes or other blood sugar problems
  • thyroid disease
  • kidney disease
  • liver disease
  1. You have an allergy to sulfonamide medicines.
    One of the active ingredients of dorzolamide/timolol is a sulfonamide-related compound. Therefore, if you are allergic to sulfonamide medicines you may be allergic to dorzolamide with timolol eye drops. Check with your doctor or pharmacist if you are not sure whether you are allergic to sulfonamides.
  2. You are already using another beta-blocker eye drop
    It is not recommended to use two beta-blocker eye drops at the same time.
  3. You have a history of allergic problems, including eczema, hives or hay fever.
  4. You are currently pregnant or you plan to become pregnant. Do not take this medicine whilst pregnant until you and your doctor have discussed the risks and benefits involved.
  5. You are currently breastfeeding or you plan to breastfeed. Do not take this medicine whilst breastfeeding until you and your doctor have discussed the risks and benefits involved.
  6. You are planning to have surgery.
  7. You are taking or are planning to take any other medicines. This includes vitamins and supplements that are available from your pharmacy, supermarket or health food shop.

Taking other medicines

Some medicines may interact with dorzolamide/timolol. These include:

  • medicines for high blood pressure or heart conditions, including a group of medicines called beta-blockers
  • quinidine, a medicine used to treat irregular heart beats
  • medicines to treat diabetes
  • tablets used to treat glaucoma
  • large amounts of aspirin or salicylates
  • medicines used to treat depression

If you are taking any of these you may need a different dose or you may need to take different medicines.

Other medicines not listed above may also interact with dorzolamide/timolol.

How to take this medicine

Follow carefully all directions given to you by your doctor. Their instructions may be different to the information in this leaflet.

How much to take

Your doctor will tell you how many drops you need to use each day. This will depend on your condition and whether you are taking any other medicines.

Do not stop taking your medicine or change your dosage without first checking with your doctor.

The usual dose for adults is one drop of dorzolamide/timolol twice a day, in either one or both eyes.

After using dorzolamide/timolol, wait at least 10 minutes before putting any other eye drops in your eye(s).

How to take it

You may find it easier to put drops in your eye while you are sitting or lying down.

Before opening the bottle for the first time, make sure the safety seal joining the cap to the bottle is not broken. If it is, do not use the bottle and return it to your pharmacist.

You will notice a small space between the cap and the bottle, this is normal.

If you are wearing soft contact lenses, remove them before putting the drops in your eye.

  1. Wash your hands well with soap and water.
  2. Unscrew the cap and break it off from the seal.
  3. Place the cap upside down on a flat surface. Do not touch the inside of the cap. This will help keep the inside of the cap clean and keep germs out of the eye drops.
  4. Use your finger to gently pull down the lower eyelid of the affected eye.
  5. Tilt your head back and look up.
  6. Place the tip of the bottle close to your lower eyelid. Do not let it touch your eye.
  7. Squeeze the bottle gently so that only drop goes into your eye, then release the lower eyelid.
  8. Close your eye and keep it closed. Do not blink or rub your eye.
  9. While your eye is still closed, place your index finger against the inside corner of your eye and press against your nose for about two minutes. This will help to stop the medicine from draining through the tear duct to the nose and throat, from where it can be absorbed into other parts of your body. Ask your doctor or pharmacist for more specific instructions on this technique.
  10. Screw the cap back on the bottle, sealing it tightly. Do not over tighten the cap.
  11. Wash your hands again with soap and water to remove any residue.

Wait at least 15 minutes before replacing your contact lenses.

Be careful not to touch the dropper tip against your eye, eyelid or anything else to avoid contaminating the eye drops.

Contaminated eye drops may give you an eye infection.

You may feel a slight burning sensation in the eye shortly after using the eye drops.

If this persists, or is very uncomfortable, contact your doctor or pharmacist.

When to take it

Use dorzolamide/timolol every day, at about the same time each day, unless your doctor tells you otherwise.

Using your eye drops at the same time each day will have the best effect on your eye pressure. It will also help you remember when to use the eye drops.

After using dorzolamide/timolol, wait at least 10 minutes before putting any other eye drops in your eye(s).

It does not matter if you take it before, with or after food.

How long to take it for

Dorzolamide/timolol helps control your condition but does not cure it.

Therefore dorzolamide/timolol must be used every day. Continue using dorzolamide/timolol for as long as your doctor prescribes.

Make sure you have enough of this medicine to last over weekends and holidays.

If you forget to take it

If it is almost time to take your next dose, skip the missed dose and take your next dose at the usual time. Otherwise, take it as soon as you remember and then go back to taking your medicine as you would normally.

Do not take a double dose to make up for missed doses.

This may increase the chance of you experiencing side effects.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints to help you remember.

If you take too much (overdose)

If you think that you or anyone else may have taken too much of this medicine, immediately telephone your doctor or the Poisons Information Centre (Tel: 13 11 26 in Australia) for advice. Alternatively, go to the Accident and Emergency department at your nearest hospital.

Do this even if there are no signs of discomfort or poisoning. You may need urgent medical attention.

While you are taking this medicine

Things you must do

Have your eye pressure checked when your eye specialist says, to make sure dorzolamide/timolol is working.

If you develop an eye infection, receive an eye injury, or have eye surgery tell your doctor.

Your doctor may tell you to use a new container of the eye drops because of possible contamination of the old one, or may advise to stop your treatment with the eye drops.

Tell your doctor that you are taking this medicine if:

  • you are about to be started on any new medicine
  • you are pregnant or are planning to become pregnant
  • you are breastfeeding or are planning to breast-feed
  • you are going to have surgery or are going into hospital.

Go to your doctor or eye specialist regularly for a check-up.

Tell any other doctors, dentists and pharmacists who are treating you that you take this medicine.

Things you must not do

Do not:

  • Give this medicine to anyone else, even if their symptoms seem similar to yours.
  • Take your medicine to treat any other condition unless your doctor tells you to.
  • Stop taking your medicine, or change the dosage, without first checking with your doctor.
    If you stop using your medicine, your eye pressure may rise again and damage to your eye may occur.

Things to be careful of

Be careful when driving or operating machinery until you know how this medicine affects you.

Dorzolamide/timolol generally does not cause any problems with your ability to drive a car or operate machinery. However, it may cause blurred vision or dizziness in some people. Make sure you know how you react to dorzolamide/timolol or that your vision is clear before you drive a car or operate machinery.

Possible side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking dorzolamide/timolol or if you have any questions or concerns.

Do not be alarmed by the following lists of side effects. You may not experience any of them. All medicines can have side effects. Sometimes they are serious but most of the time they are not. You may need medical treatment if you get some of the side effects.

Tell your doctor if you notice any of the following:

  • problems with your eye(s) such as:
    - blurred vision, double vision or other visual problems
    - allergic reactions including redness, swelling and/or itching of the eye
    - burning and stinging of the eyes, eye pain
    - watering of the eyes or discharge
    - conjunctivitis
    - irritation or feeling of having something in the eye, dry eyes
    - swelling of the eyelids, drooping of the eyelids
  • difficulty thinking or working because of:
    - headache
    - tiredness, weakness
    - ringing or buzzing in the ears
    - difficulty in sleeping, nightmares
    - changes in mood such as depression, memory loss
    - mouth or stomach problems:
    - feeling sick (nausea), upset stomach, stomach pain
    - diarrhoea
    - bitter or abnormal taste, dry mouth
  • respiratory problems:
    - cough
    - sore throat and discomfort when swallowing
    - cold or flu-like symptoms such as sneezing, runny nose, cough, red or infected throat
    - feeling of tension or fullness in the nose or cheeks and behind your eyes, throbbing ache, also called sinusitis
  • changes in the way your hands and feet feel such as:
    - cold hands or feet
    - numbness, tingling and colour change (white, blue then red) in fingers when exposed to the cold (Raynaud's Phenomenon)
    - numbness or tingling in the fingers or toes
  • symptoms of a urinary tract infection including the urge to urinate frequently and in small amounts, or painful burning when passing urine
  • back pain
  • nose bleeds
  • hair loss or thinning
  • less desire for sex.

Tell your doctor as soon as possible if you notice any of the following.

These may be serious side effects and you may need medical attention:

  • fast or irregular heartbeats, also called palpitations
  • slow or irregular heart beats
  • dizziness and light-headedness, which may be due to low blood pressure
  • swelling of the hands or feet
  • swelling of the face, lips, mouth, tongue or throat which may cause difficulty in breathing or swallowing
  • severe and sudden onset of pinkish, itchy swellings on the skin, also called hives or nettlerash
  • skin rash, itchiness.

Serious side effects are rare.

Other side effects not listed above may also occur in some patients.

Tell your doctor if you notice any other effects

Allergic reactions

If you think you are having an allergic reaction to dorzolamide/timolol, do not take any more of this medicine and tell your doctor immediately or go to the Accident and Emergency department at your nearest hospital.

Symptoms of an allergic reaction may include some or all of the following:

  • shortness of breath, wheezing or difficulty breathing
  • swelling of the face, lips, tongue, throat or other parts of the body
  • rash, itching or hives on the skin
  • fainting
  • hay fever-like symptoms.

Storage and disposal

Storage

Keep your medicine in its original packaging until it is time to take it.

If you take your medicine out of its original packaging it may not keep well.

Keep your medicine in a cool dry place where the temperature will stay below 25°C. Protect from light.

Do not store your medicine, or any other medicine, in the bathroom or near a sink. Do not leave it on a window sill or in the car. Heat and dampness can destroy some medicines.

Keep this medicine where children cannot reach it.

A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Do not leave the cap off the bottle for any length of time to avoid contaminating the eye drops.

Disposal

Write the date on the bottle when you open the eye drops and throw out any remaining solution after four weeks.

Dorzolamide/timolol contains a preservative which helps prevent germs growing in the solution for the first four weeks after opening the bottle. After this time there is a greater risk that the drops may become contaminated and cause an eye infection. A new bottle should be opened.

If your doctor tells you to stop taking this medicine or it has passed its expiry date, your pharmacist can dispose of the remaining medicine safely.

Product description

What APO-Dorzolamide/Timolol Eye Drops looks like

Dorzolamide/Timolol eye drop is a clear, colourless to nearly colourless, slightly viscous solution.

The eye drops come in a 5 mL plastic bottle with a dropper and screw cap.

Ingredients

Each eye drop contains 2% w/v of dorzolamide (as hydrochloride) and 0.5% w/v timolol (as maleate) as the active ingredient.

It also contains the following inactive ingredients:

  • hyetellose
  • mannitol
  • sodium citrate dihydrate
  • benzalkonium chloride
  • sodium hydroxide
  • water for injections

This medicine is gluten-free, lactose-free, sucrose-free, tartrazine-free and free of other azo dyes.

Australian Registration Numbers

APO-Dorzolamide/Timolol 20/5 eye drops (bottle): AUST R 267121.

Sponsor

Apotex Pty Ltd
16 Giffnock Avenue
Macquarie Park NSW 2113

APO and APOTEX are registered trade marks of Apotex Inc.

This leaflet was last updated in:
December 2016

BRAND INFORMATION

Brand name

APO-Dorzolamide/Timolol 20/5 Eye Drops

Active ingredient

Dorzolamide; Timolol

Schedule

S4

 

1 Name of Medicine

Dorzolamide hydrochloride and timolol maleate.

2 Qualitative and Quantitative Composition

Each millilitre of dorzolamide/timolol combination eye drops contains 20.0 mg (2% w/v) dorzolamide (22.3 mg of dorzolamide hydrochloride) and 5.0 mg (0.5% w/v) timolol (6.8 mg of timolol maleate) as the active ingredients.
It is a sterile, isotonic, buffered, slightly viscous, aqueous solution.

List of excipient(s) with known effect.

Benzalkonium chloride.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Eye drops, solution.
Clear, colourless to nearly colourless, slightly viscous solution.

4 Clinical Particulars

4.1 Therapeutic Indications

Dorzolamide/timolol combination eye drops is indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma when concomitant therapy is appropriate.

4.2 Dose and Method of Administration

APO-Dorzolamide/Timolol 20/5 Eye Drops are intended for ophthalmic administration and for individual patient use only.

Dosage.

The dose is one drop of dorzolamide/timolol combination (2.0%/0.5%) eye drops in the affected eye(s) two times daily.
When substituting dorzolamide/timolol combination eye drops for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start dorzolamide/timolol combination eye drops on the next day.
If another topical ophthalmic agent is being used, dorzolamide/timolol combination eye drops and the other agent should be administered at least ten minutes apart.
Systemic absorption can be minimised by pressure on the tear duct immediately after application of the eye drop.
Efficacy in paediatric patients has not been established. Safety in paediatric patients below the age of 2 years has not been established (For information regarding safety in paediatric patients ≥ 2 and < 6 years of age, see Section 4.4 Special Warnings and Precautions for Use, Paediatric use).

4.3 Contraindications

Dorzolamide/timolol combination eye drops is contraindicated in patients with:
reactive airway disease, bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease;
sinus bradycardia, sino-atrial block, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock;
hypersensitivity to any component of this product.
The above are based on the components and are not unique to the combination.

4.4 Special Warnings and Precautions for Use

The timolol component is a beta-blocker and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions found with systemic administration of beta-blockers may occur with topical administration.

Cardio-respiratory reactions.

Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
In patients without a history of cardiac failure, continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, dorzolamide/timolol combination eye drops should be discontinued.
Because of the timolol maleate component, cardiac failure should be adequately controlled before beginning therapy with dorzolamide/timolol combination eye drops. Patients with a history of cardiovascular disease, including cardiac failure, should be watched for signs of deterioration of these diseases and pulse rates should be checked.
Due to its negative effect on conduction time, beta-blockers should be given with caution to patients with first degree heart block.
The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or levarterenol.
Because of potential effects of beta-adrenergic blocking agents relative to blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with dorzolamide/timolol combination eye drops, alternative therapy should be considered.
Respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and rarely death in association with cardiac failure, have been reported following administration of timolol maleate ophthalmic solution.
In patients with mild/moderate chronic obstructive pulmonary disease (COPD), dorzolamide/timolol combination eye drops should be used with caution, and only if the potential benefit outweighs the potential risk.

Vascular disorders.

Patients with severe peripheral circulatory disturbance/disorders (e.g. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

Masking of hypoglycaemic symptoms in patients with diabetes mellitus.

Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycaemic agents. Beta-adrenergic blocking agents may mask the signs and symptoms of acute hypoglycaemia.

Masking of thyrotoxicosis.

Beta-adrenergic blocking agents may mask certain clinical signs of hyperthyroidism (e.g. tachycardia). Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents which might precipitate a thyroid storm.

Surgical anaesthesia.

The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists such as isoproterenol, dopamine, dobutamine or levarterenol (see Section 4.9 Overdose).

Use in hepatic impairment.

Dorzolamide/timolol combination eye drops has not been studied in patients with hepatic impairment and therefore should be used with caution in such patients.

Use in renal impairment.

Dorzolamide/timolol combination eye drops has not been studied in patients with severe renal impairment (CrCl < 30 millilitre/min). Because dorzolamide hydrochloride and its metabolite are excreted predominantly by the kidney, dorzolamide/timolol combination eye drops is not recommended in such patients.

Immunology and hypersensitivity.

The dorzolamide component is a sulfonamide and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions found with systemic administration of sulfonamides may occur with topical administration, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If signs of serious reactions or hypersensitivity occur, discontinue use of this preparation.
In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of dorzolamide hydrochloride ophthalmic solution. Some of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. Similar reactions have been reported with dorzolamide/timolol combination eye drops. If such reactions are observed, discontinuation of treatment with dorzolamide/timolol combination eye drops should be considered.
While taking β-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to accidental, diagnostic, or therapeutic repeated challenge with such allergens. Such patients may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.

Concomitant therapy.

There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving oral and topical carbonic anhydrase inhibitors concomitantly. The concomitant administration of dorzolamide/timolol combination eye drops and oral carbonic anhydrase inhibitors has not been studied and is not recommended.
Patients who are already receiving a beta-adrenergic blocking agent systemically and who are given dorzolamide/timolol combination eye drops should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta-blockade. The use of two topical beta-adrenergic blocking agents is not recommended.

Other.

The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide/timolol combination eye drops has not been studied in patients with acute angle-closure glaucoma.
Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide, dorzolamide) after filtration procedures.
There is an increased potential for developing corneal oedema in patients with low endothelial cell counts. Precautions should be used when prescribing dorzolamide/timolol combination eye drops to this group of patients.
Beta-adrenergic blockade has been reported to increase muscle weakness consistent with certain myasthenic symptoms (e.g. diplopia, ptosis and generalised weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenic symptoms.
There have been reports of bacterial keratitis associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.
Patients should be advised that if they develop an intercurrent ocular condition (e.g. trauma, ocular surgery or infection) or any ocular reactions, particularly conjunctivitis and lid reactions they should immediately seek their physician's advice concerning the continued use of the product.
Ophthalmic solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

Contact lens use.

Dorzolamide/timolol combination eye drops contains the preservative benzalkonium chloride, which may be deposited in soft contact lenses; therefore, dorzolamide/timolol combination eye drops should not be administered while wearing these lenses.
The lenses should be removed before application of the drops and not be reinserted earlier than 15 minutes after use.

Use in the elderly.

Of the total number of patients in clinical studies of dorzolamide/timolol combination eye drops, 49% were 65 years of age and over, while 13% were 75 years of age and over. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Paediatric use.

The safety and usage of 2% dorzolamide hydrochloride ophthalmic solution has been tested in a clinical study of three months' duration in children under the age of 6 years. In this study, patients under 6 and greater than 2 years of age whose IOP was not controlled with monotherapy with dorzolamide or 0.5% timolol gel forming solution received dorzolamide/timolol combination eye drops. Nineteen of 66 patients randomised to dorzolamide monotherapy and 11 of 35 patients randomised to timolol monotherapy were transferred to dorzolamide/timolol combination eye drops. Of those 30 patients transferred to preserved dorzolamide/timolol combination eye drops, three patients had the following drug related adverse events: cough, burning/stinging eye and ocular injection.

Effects on laboratory tests.

Dorzolamide/timolol combination eye drops was not associated with clinically meaningful electrolyte disturbances.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Specific drug interaction studies have not been performed with dorzolamide/timolol combination eye drops.
In clinical studies, dorzolamide/timolol combination eye drops were used concomitantly with the following systemic medications without evidence of adverse interactions: ACE-inhibitors, calcium channel blockers, diuretics, non-steroidal anti-inflammatory drugs including aspirin, and hormones (e.g. oestrogen, insulin, thyroxine).
However, the potential exists for additive effects and production of hypotension and/or marked bradycardia when timolol maleate ophthalmic solution is administered together with calcium channel blockers, catecholamine-depleting drugs, antiarrhythmics, parasympathomimetics or beta-adrenergic blocking agents.
Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, SSRIs) and timolol.
The dorzolamide component of dorzolamide/timolol combination eye drops is a carbonic anhydrase inhibitor and although administered topically, is absorbed systemically. In clinical studies, dorzolamide hydrochloride ophthalmic solution was not associated with acid-base disturbances. However, these disturbances have been reported with oral carbonic anhydrase inhibitors and have in some instances, resulted in drug interactions (e.g. toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving dorzolamide/timolol combination eye drops.
Although dorzolamide/timolol combination eye drops used alone has little or no effect on pupil size, mydriasis resulting from concomitant use of timolol maleate and adrenaline has been reported occasionally.
β-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. Caution should be exercised in patients using these drugs concomitantly. There have been no reports of exacerbation of rebound hypertension with ophthalmic timolol maleate.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Dorzolamide hydrochloride.

In reproduction studies of dorzolamide hydrochloride in rats, there were no adverse effects on the reproductive capacity of males or females at oral doses up to 15 and 7.5 mg/kg/day, respectively.

Timolol maleate.

Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses of up to 100 mg/kg/day.
(Category C)
Beta-adrenergic blocking agents may cause pharmacological effects such as bradycardia in the foetus and newborn infant.
Developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of ≥ 2.5 mg/kg/day (foetal red blood cell Cmax was approximately twice the maternal red blood cell Cmax after the recommended human ophthalmic dose) revealed malformations of the vertebral bodies. These malformations occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased foetal weights. No treatment-related malformations were seen at 1.0 mg/kg/day. There were no treatment-related foetal malformations in developmental toxicity studies with dorzolamide hydrochloride in rats at oral doses up to 10 mg/kg/day.
Developmental studies with timolol in mice, rats and rabbits at oral doses up to 50 mg/kg/day demonstrated no evidence of foetal malformations. Although delayed foetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of the offspring. Doses of 1000 mg/kg/day were maternotoxic in mice and resulted in an increased number of foetal resorptions. Increased foetal resorptions were also seen in rabbits at oral doses of 100 mg/kg/day, in this case without apparent maternotoxicity.
There are no adequate and well-controlled studies in pregnant women. Dorzolamide/timolol combination eye drops should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Dorzolamide was excreted in the milk of lactating rats and decreases in the body weight gain of the offspring were seen during lactation after an oral dose of 7.5 mg/kg/day. A slight delay in postnatal development (incisor eruption, vaginal canalisation and eye openings), secondary to lower foetal body weight, was noted. It is not known whether this drug is excreted in human milk.
Timolol has been detected in human milk following oral and ophthalmic drug administration. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from dorzolamide/timolol combination eye drops, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

4.7 Effects on Ability to Drive and Use Machines

There are side effects associated with dorzolamide/timolol combination eye drops that may affect some patients' ability to drive and/or operate machinery. See Section 4.8 Adverse Effects (Undesirable Effects).

4.8 Adverse Effects (Undesirable Effects)

During clinical studies, 1035 patients were treated with dorzolamide/timolol combination (2.0%/0.5%) eye drops. Approximately 2.4% of all patients discontinued therapy with dorzolamide/timolol combination eye drops because of local ocular adverse reactions. Approximately 1.2% of all patients discontinued because of local adverse reactions suggestive of allergy or hypersensitivity.
The most frequently reported drug-related adverse effects were: ocular burning and stinging, taste perversion, corneal erosion, conjunctival injection, blurred vision, tearing, and ocular itching. Urolithiasis was reported rarely.

Clinical adverse experiences in ≥ 1% of patients receiving combination therapy in phase III studies.

Body as a whole.

Abdominal pain.

Cardiovascular.

Hypertension.

Digestive.

Dyspepsia, nausea.

Musculoskeletal.

Back pain.

Nervous/psychiatric.

Dizziness, headache, paraesthesia.

Respiratory.

Bronchitis, cough, upper respiratory infection, influenza, pharyngitis, sinusitis.

Special senses.

Blepharitis, blurred vision, burning or stinging of the eye, conjunctivitis, visual field defect, eye discharge, eyelid oedema, corneal erosion, foreign body sensation, conjunctival injection, eye itching, lens opacity, eye pain, taste perversion, corneal staining, eye tearing.

Urogenital.

Urinary tract infection.
The following adverse reactions have been reported in post-marketing experience: dyspnoea, respiratory failure, contact dermatitis, bradycardia, heart block, choroidal detachment following filtration surgery, nausea, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Additional side effects that have been seen with one of the components and may be potential side effects of dorzolamide/timolol combination eye drops are:

Dorzolamide hydrochloride.

Headache; eyelid inflammation; eyelid irritation; eyelid crusting; asthenia/fatigue; iridocyclitis; rash; dizziness; paraesthesia; superficial punctate keratitis; transient myopia (which resolved upon discontinuation of therapy); signs and symptoms of local reactions including palpebral reactions and systemic allergic reactions including angioedema, bronchospasm, urticarial and pruritus; contact dermatitis, epistaxis, throat irritation, dry mouth. Choroidal detachment has been reported with administration of dorzolamide after filtration procedures.

Timolol maleate (topical formulation).

Signs and symptoms of ocular irritation, including conjunctivitis, blepharitis, keratitis, and decreased corneal sensitivity, dry eyes; visual disturbances, including refractive changes (due to withdrawal of miotic therapy in some cases), diplopia, and ptosis; choroidal detachment following filtration surgery; tinnitus; bradycardia; arrhythmia; hypotension; syncope; heart block; cerebrovascular accident; cerebral ischaemia; congestive heart failure; palpitation; cardiac arrest; oedema, claudication, Raynaud's phenomenon, cold hands and feet; bronchospasm (predominantly in patients with pre-existing bronchospastic disease); cough; respiratory failure; dyspnoea; headache; asthenia; fatigue; chest pain; alopecia; psoriasiform rash or exacerbation of psoriasis; signs and symptoms of allergic reactions including anaphylaxis, angioedema, urticaria, localised and generalised rash; dizziness; depression, insomnia, nightmares, memory loss; increase in signs and symptoms of myasthenia gravis, paraesthesia; diarrhoea, dyspepsia, dry mouth; abdominal pain; decreased libido, Peyronie's disease; sexual dysfunction; systemic lupus erythematosus, myalgia.

Timolol maleate (systemic formulation).

Extremity pain; decreased exercise tolerance; AV block (2nd or 3rd degree); sinoatrial block; pulmonary oedema; worsening of arterial insufficiency; worsening of angina pectoris; vasodilation; vomiting; diarrhoea, hyperglycaemia; hypoglycaemia; pruritus; sweating; exfoliative dermatitis; arthralgia; vertigo; local weakness; diminished concentration; increased dreaming; nonthrombocytopenic purpura; rales; impotence; micturition difficulties.
Clinically important changes in standard laboratory parameters were rarely associated with the administration of systemic timolol maleate. Slight increases in serum urea, serum potassium, serum uric acid and triglycerides; and slight decreases in haemoglobin, haematocrit and HDL-cholesterol occurred; but were not progressive or associated with clinical manifestations.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems and contact Apotex Medical Information Enquiries/Adverse Drug Reaction Reporting on 1800 195 055.

4.9 Overdose

No data are available with regard to human overdosage by accidental or deliberate ingestion of dorzolamide/timolol combination eye drops.

Symptoms.

There have been reports of inadvertent overdosage with timolol maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. The most common signs and symptoms to be expected with overdosage of dorzolamide are electrolyte imbalance, development of an acidotic state, and possibly central nervous system effects.

Treatment.

Treatment should be symptomatic and supportive. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that timolol does not dialyse readily.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

Dorzolamide/timolol combination eye drops is comprised of two components: dorzolamide hydrochloride and timolol maleate. It is the first combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent. Each of these two components decreases elevated intraocular pressure by reducing aqueous humor secretion, but does so by a different mechanism of action.
Dorzolamide hydrochloride is a potent inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport.
Timolol maleate is a nonselective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anaesthetic (membrane-stabilising) activity. The precise mechanism of action of timolol maleate in lowering intraocular pressure is not clearly established at this time, although a fluorescein study and tonography studies indicate that its predominant action may be related to reduced aqueous formation. However, in some studies, a slight increase in outflow facility was also observed.
The combined effect of these two agents results in additional intraocular pressure reduction compared to either component administered alone.
Following topical administration, dorzolamide/timolol combination eye drops reduces elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic nerve damage. Dorzolamide/timolol combination eye drops reduces intraocular pressure without the common side effects of miotics such as night blindness, accommodative spasm and pupillary constriction.

Clinical trials.

Clinical studies of up to 15 months duration (double-masked phase of up to 3 months, followed by up to 12 months open-label treatment with dorzolamide/timolol combination 2.0%/0.5% eye drops) were conducted to compare the IOP-lowering effect of dorzolamide/timolol combination b.i.d. (dosed morning and bedtime) to individually- and concomitantly-administered 0.5% timolol and 2.0% dorzolamide in patients with glaucoma or ocular hypertension for whom concomitant therapy is appropriate. This includes both untreated patients and patients inadequately controlled with timolol monotherapy. The IOP-lowering effect of dorzolamide/timolol combination b.i.d. was greater than that of monotherapy with either 2% dorzolamide t.i.d. or 0.5% timolol b.i.d. The IOP-lowering effect of dorzolamide/timolol combination b.i.d. was equivalent to that of concomitant therapy with dorzolamide b.i.d. and timolol b.i.d. The IOP lowering effect of dorzolamide/timolol combination b.i.d. was approximately 1 mmHg less than that of concomitant therapy with 2% dorzolamide t.i.d. and 0.5% timolol b.i.d.

A. Comparison to concomitant therapy (patients initiated on timolol therapy).

In a 3-month randomised, double-masked, parallel clinical study, patients receiving dorzolamide/timolol combination (2.0%/0.5% eye drops) b.i.d. (n = 151) were compared to patients receiving 0.5% timolol b.i.d. plus 2.0% dorzolamide b.i.d. concomitantly (n = 148). At morning trough (hour 0) and morning peak (hour 2), patients receiving dorzolamide/timolol combination experienced IOP-lowering that was equivalent to that seen in the patients receiving the individual components concomitantly. (Equivalence was defined as a 90% confidence that the absolute difference between mean change in IOP for the 2 treatments was less than 1.5 mmHg). The following reductions in IOP were observed relative to the baseline value obtained after 2 weeks of 0.5% timolol b.i.d. monotherapy. See Table 1.
Four 3-month randomized, double-masked parallel clinical studies were conducted to compare dorzolamide/timolol combination b.i.d. to 0.5% timolol b.i.d. monotherapy and 2.0% dorzolamide t.i.d. monotherapy. Two studies (n=685) were conducted in patients with baseline IOP ≤ 24 mmHg after a washout of all previous ocular hypotensive therapies. The other two studies (n=500) were conducted in patients with elevated IOP ≤ 22 mmHg inadequately controlled after 3 weeks of 0.5% timolol b.i.d monotherapy. Based upon post-hoc analyses of the combined washout studies data and the combined timolol run-in studies data, the estimated difference between the IOP-lowering effects of dorzolamide/timolol combination and dorzolamide was 1.9 - 2.4 mmHg (7.8 - 8.9%) at morning trough (hour 0) and 2.3 - 2.7 mmHg (9.9%) at morning peak (hour 2), while the estimated difference between the IOP-lowering effects of dorzolamide/timolol combination and timolol was 0.8 - 0.9 mmHg (2.9 - 3.5%) at morning trough (hour 0) and 1.8 - 2.3 mmHg (6.9 - 9.0%) at morning peak (hour 2). These differences are statistically significant in favour of the combination.

Long-term studies.

Open-label extensions of two studies were conducted for up to 12 months. During this period, the IOP-lowering effect of dorzolamide/timolol combination (2.0%/0.5% eye drops) b.i.d was demonstrated throughout the day and this effect was maintained during the follow up period.

5.2 Pharmacokinetic Properties

Dorzolamide hydrochloride.

Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the drug to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors.
When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free drug in plasma are maintained. The parent drug forms a single N-desethyl metabolite that inhibits CA-II less potently than the parent drug but also inhibits a less active isoenzyme (CA-I). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.
To simulate maximum exposure after long term topical ocular administration, dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 4 mg/day closely approximates the maximum amount of drug delivered by topical ocular administration of dorzolamide 2% t.i.d. Steady state was reached within 13 weeks. At steady state, there was virtually no free drug or metabolite in plasma; CA inhibition in RBCs was less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar pharmacokinetic results were observed after chronic, topical administration of dorzolamide hydrochloride. However, some elderly patients with renal impairment (estimated CrCl 30 - 60 millilitre/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition and no clinically significant systemic side effects were directly attributable to this finding.

Timolol maleate.

In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily topical administration of timolol maleate ophthalmic solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 nanogram/mL and following afternoon dosing was less than the lower limit of quantification of the assay, 0.375 nanogram/mL.

5.3 Preclinical Safety Data

Genotoxicity.

Dorzolamide hydrochloride.

Dorzolamide showed no mutagenic potential in a series of standard assays for gene mutations, chromosomal damage and DNA damage.

Timolol maleate.

In vitro and in vivo studies (Ames test, neoplastic cell transformation assay, cytogenetic assay and micronucleus test in mice) showed no genotoxicity of timolol.

Carcinogenicity.

Dorzolamide hydrochloride.

In a two-year study of dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder papillomas were seen in male rats in the highest dosage group of 20 mg/kg/day. No treatment-related tumours were seen in a 21-month study in male and female mice given oral doses up to 75 and 37.5 mg/kg/day, respectively.
The increased incidence of urinary bladder papillomas seen in the high-dose male rats appears to be a class-effect of carbonic anhydrase inhibitors in rats. Rats are particularly prone to developing papillomas in response to foreign bodies, compounds causing crystalluria and diverse sodium salts.
No changes in bladder urothelium were seen in dogs given oral dorzolamide hydrochloride for one year at 2 mg/kg/day or monkeys dosed topically to the eye at 0.4 mg/kg/day for one year.

Timolol maleate.

In a 2-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day. Similar differences were not observed in rats administered oral doses of 100 mg/kg/day.
In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary adenocarcinomas in female mice at 500 mg/kg/day, but not at 50 mg/kg/day. In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumours was again observed at 500 mg/kg/day.
The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg, but not at doses of 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumours has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.

6 Pharmaceutical Particulars

6.1 List of Excipients

Sodium citrate dihydrate, hyetellose, sodium hydroxide, mannitol, water for injections, benzalkonium chloride (0.0075%) is added as preservative.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Protect from light. Store in original container.
Discard product 4 weeks after opening.

6.5 Nature and Contents of Container

APO-Dorzolamide/Timolol 20/5 Eye Drops.

Bottle (translucent LDPE bottle and nozzle, with white HDPE cap).
Pack size: 5 mL.
AUST R 267121.
APO and APOTEX are registered trade marks of Apotex Inc.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

Dorzolamide hydrochloride is a white to off-white, free flowing crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.
Timolol maleate is a white, odourless, crystalline powder which is soluble in water, methanol, and alcohol.

Chemical structure.

Dorzolamide hydrochloride.


Chemical Name: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno [2,3-b] thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride.
Molecular Formula: C10H17N2O4S3Cl.
Molecular Weight: 360.91.
pKa: 6.35 and 8.5.
Log P: 1.96.

Chemical structure.

Timolol maleate.


Chemical Name: (S)-1-[(1,1-dimethylethyl) amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl] oxy]-2-propanol, (Z)-2-butenedioate (1:1) (salt).
Molecular Formula: C13H24N4O3S.C4H4O4.
Molecular Weight: 432.50.
pKa: 9.2.
Log P: 1.8.

CAS number.

Dorzolamide hydrochloride.

130693-82-2.

Timolol maleate.

26921-17-5.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Summary Table of Changes